Template:KDRG

Revision as of 18:17, 20 August 2024 by Kosar Doraghi (talk | contribs) (→‎Pages Authored/Co-authored/Collaborated)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Kosar Doraghi, M.D.[1]

Kosar Doraghi, M.D.

Current Position

Associate Editor-in-Chief, Beth Israel Deaconess Medical Center by Harvard Medical School, Boston, Massachusetts, USA, WikiDoc Scholar


Pages Authored/Co-authored/Collaborated

  1. NEXOBRID
  2. RELYVRIO
  3. Deucravacitinib
  4. Ublituximab-xiiy
  5. LYTGOBI- futibatinib
  6. Tapinarof
  7. Spevigo- spesolimab-sbz
  8. Vericiguat
  9. Dasiglucagon
  10. Ponesimod
  11. Lasmiditan
  12. Nirogacestat
  13. Nedosiran
  14. Ryzneuta
  15. Endocarditis overview
  16. Sparsentan
  17. BRENZAVVY- bexagliflozin
  18. COPD Patient with suspected Exacerbation(New GOLD 2024 Recommendation)
  19. Nirsevimab
  20. Xacduro- sulbactam and durlobactam
  21. EXXUA
  22. Somatrogon-ghla
  23. Aprocitentan
  24. WINREVAIR
  25. Xolremdi
  26. Rytelo
  27. Chronic obstructive pulmonary disease history and symptoms New Guidelines 2024
  28. Chronic renal failure overview New Guidelines 2024
  29. Clinical assessment of lower extremity peripheral arterial disease New Guidelines 2024
Retrieved from "https://www.wikidoc.org/index.php?title=Template:KDRG&oldid=1739181"